Enteric Adenovirus Gastroenteritis in Under-Five Children, Kano-Nigeria
Abstract
Adenoviruses have been implicated in many outbreaks and sporadic cases of pediatric gastroenteritis.
This study aimed to determine the prevalence and circulating serotype(s) of enteric adenoviruses among under-five children with diarrheal diseases in Kano, Nigeria.
This was a multicentered hospital-based cross-sectional study involving 250 under-five children recruited from Murtala Muhammad Specialist Hospital, Muhammad Abdullahi Wase Teaching Hospital and Hasiya Bayero Paediatric Hospital.
Enteric adenovirus F40/F41 were checked in the stools of children exhibiting symptoms of gastroenteritis, diarrhea, and/or vomiting by nested PCR amplification of the adenovirus Hexa/E1B regions and positive samples characterized by sequencing and phylogenetic analysis.
Data generated were analyzed using descriptive statistics, and the association between the variables was checked by the Chi-square test. A P value <0.05 was considered statistically significant.
The nested PCR result shows that 7 (2.8%) out of the 250 stools were positive for enteric adenovirus (group F), with only serotype F41 detected within the cohort examined. The isolates were more closely related to KJ425126 from Gabon. The results highlighted that fever and vomiting are prominent features of adenovirus F41 gastroenteritis and children 1–2 years especially males were mostly affected.
The study improved our knowledge and understanding of the role of enteric adenovirus in under-five gastroenteritis and suggests that…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.